Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
This clinical trial is studying induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin. Radioisotope therapy, such as iobenguane I 131, releases radiation that kills tumor cells. Drugs used in chemotherapy, such as carboplatin, etoposide, busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that are destroyed by iobenguane I 131 and chemotherapy.
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Stage 4S Neuroblastoma
Drug: doxorubicin hydrochloride
Drug: irinotecan hydrochloride
Other: pharmacological study
Other: questionnaire administration
Procedure: autologous hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy
Radiation: external beam radiation therapy
Radiation: intensity-modulated radiation therapy
Drug: topotecan hydrochloride
Drug: etoposide phosphate
Drug: vincristine sulfate
Radiation: iobenguane I 131
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG/Irinotecan/Vincristine Followed by Myeloablative Busulfan-Melphalan (Bu-Mel) for Newly Diagnosed High-Risk Neuroblastoma|
- Proportion of MIBG avid patients who are able to be treated with 131I-MIBG/irinotecan/vincristine [ Time Frame: Up to 6 weeks after course 5 of induction ] [ Designated as safety issue: No ]This proportion will be calculated as the number of MIBG avid patients who receive 131I-MIBG/irinotecan/vincristine divided by the number of patients evaluable for the feasibility of MIBG endpoint. The definition of receive 131I-MIBG/irinotecan/vincristine is receiving 131I-MIBG infusion.
- Proportion of MIBG avid patients who are able to be treated with 131I-MIBG/irinotecan/vincristine and then Bu/Mel [ Time Frame: Day -6 of conditioning ] [ Designated as safety issue: No ]This proportion will be calculated as the number of MIBG avid patients who receive 131I-MIBG/irinotecan/vincristine and Bu/Mel divided by the number of patients evaluable for the feasibility of MIBG and Bu/Mel consolidation endpoint. The definition of receiving Bu/Mel conditioning is receiving the first dose of planned Busulfan on Day -6 of conditioning.
- Percentage of average per capita income encompassed by the total of travel + housing + lost wages [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Patient/caregiver surveys will provide the information about travel for each patient. Cost of travel for each person will be determined using standard mileage reimbursement rates. Standard federal per diem rates will be utilized for families who stay in a hotel. Lost wages will be calculated for up to a maximum of 2 adults. In order to determine if the 'out-of-pocket' costs are less than 10% of yearly income, expenditures will be totaled and compared to the average per capita income, assuming 52-weeks with a 40-hour work week.
- Proportion of eligible high-risk patients accrued to the study [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
- 1-year event-free survival rate [ Time Frame: Time from enrollment to the first occurrence of relapse, progression, secondary malignancy or death, assessed at 1 year ] [ Designated as safety issue: No ]A 95% confidence interval will be calculated for the 1-year EFS rate. We will perform a comparison of the 1-year EFS rate on this study versus a hypothesized model of the standard using the methodology of Woolson.
- Response rate, defined as the proportion of evaluable patients who attain a response of PR or better at the end of 131I-MIBG/irinotecan/vincristine + Bu/Mel therapy and local XRT [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Response will be determined using the International Response Criteria.
- Incidence of SOS [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]
|Study Start Date:||October 2010|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: Treatment (131I-MIBG/irinotecan/vincristine)
See Detailed Description
Drug: doxorubicin hydrochloride
Other Names:Drug: irinotecan hydrochloride
Other Names:Other: pharmacological study
Other Name: pharmacological studiesOther: questionnaire administration
Ancillary studiesProcedure: autologous hematopoietic stem cell transplantation
Undergo autologous in vitro-treated peripheral blood stem cell transplantationProcedure: in vitro-treated peripheral blood stem cell transplantation
Undergo autologous in vitro-treated peripheral blood stem cell transplantation
Other Names:Procedure: therapeutic conventional surgery
Undergo surgeryRadiation: 3-dimensional conformal radiation therapy
Other Names:Radiation: external beam radiation therapy
Other Name: EBRTRadiation: intensity-modulated radiation therapy
Other Name: IMRTDrug: cyclophosphamide
Other Names:Drug: topotecan hydrochloride
Other Names:Drug: cisplatin
Other Names:Drug: etoposide phosphate
Other Names:Drug: vincristine sulfate
Other Names:Radiation: iobenguane I 131
Other Names:Drug: busulfan
Other Names:Drug: melphalan
Other Names:Drug: isotretinoin
Hide Detailed Description
I. To assess the feasibility of treating high-risk neuroblastoma patients, age 365 days to 30 years, with an induction block of meta-iodobenzylguanidine labeled with iodine-131 (131I-MIBG)/irinotecan/vincristine delivered after multi-agent chemotherapy, and post-Induction busulfan/melphalan consolidation therapy.
I. To assess the tolerability of these regimens in these patients. II. To assess the response rate of patients treated with these regimens. III. To describe the relationship of tumor norepinephrine transporter (hNET) expression with radioiodinated MIBG uptake, at diagnosis as well as with tumor response.
IV. To assess the relative reliability of 123 I-MIBG and 18FDG-PET imaging in assessment of tumor activity at diagnosis, after 2 courses of induction chemotherapy, before surgical resection and 131I-MIBG.
V. To compare detectable tumor burden before and immediate after therapy on the 123I-MIBG diagnostic scan.
VI. To test for the relationship of occurrence of sinusoidal obstruction syndrome (SOS) to Bu/Mel or to whole-body radiation dose or delayed radiation clearance due to 131I-MIBG.
VII. To analyze busulfan first-dose pharmacokinetics as measured by area under the curve (AUC) and to relate exposure to SOS incidence.
VIII. To describe the toxicity of 131I-MIBG combined with vincristine and irinotecan given on a 5-day schedule.
OUTLINE: This is a pilot, multicenter study.
INDUCTION CHEMOTHERAPY: Patients receive 5 courses of induction therapy.
Courses 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Patients undergo peripheral blood stem cell (PBSC) collection after course 2.
Course 3 and 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide phosphate IV over 1-2 hours on days 1-3. Patients undergo surgery to remove remaining tumor following course 5.
Course 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2 and vincristine sulfate IV and doxorubicin hydrochloride IV over 24 hours on days 1-3.
Treatment repeats every 21 days for a total of 5 courses in the absence of disease progression or unacceptable toxicity. Patients without progressive disease proceed to iobenguane I 131 (^131I-MIBG) induction therapy beginning 3-6 weeks after course 5. Patients receive vincristine IV on day 0, irinotecan IV over 90 minutes on day 0-4, and iobenguane I 131 IV over 90-120 minutes on day 1.
SURGERY: Patients undergo surgery after course 4 or before consolidation therapy.
CONSOLIDATION THERAPY: Within 4-6 weeks after completion of induction therapy, patients receive busulfan IV over 2 hours every 6 hours on days -6 to -3 and melphalan IV on day -1. Patients also complete a questionnaire regarding costs for travel and accommodations during therapy. Blood samples maybe collected after the first dose of busulfan for pharmacokinetic assays.
AUTOLOGOUS STEM CELL RESCUE: Patients undergo infusion of PBSC on day 0.
RADIOTHERAPY: Beginning 28-42 days after peripheral blood stem cell infusion, patients undergo 12 fractions of external-beam radiotherapy (2D, 3D-conformal, or intensity-modulated) to all areas of residual disease, primary tumor site, and involved nodal disease.
MAINTENANCE THERAPY: Beginning 66 days after transplantation, patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for 6 courses.
After completion of study therapy, patients are followed up every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years.
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35294|
|United States, California|
|Children's Hospital Los Angeles|
|Los Angeles, California, United States, 90027|
|University of California San Francisco Medical Center-Parnassus|
|San Francisco, California, United States, 94143|
|United States, Colorado|
|Children's Hospital Colorado|
|Aurora, Colorado, United States, 80045|
|United States, District of Columbia|
|Children's National Medical Center|
|Washington, District of Columbia, United States, 20010|
|United States, Illinois|
|University of Chicago Comprehensive Cancer Center|
|Chicago, Illinois, United States, 60637-1470|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center|
|Cincinnati, Ohio, United States, 45229|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia|
|Philadelphia, Pennsylvania, United States, 19104|
|United States, Texas|
|University of Texas Southwestern Medical Center|
|Dallas, Texas, United States, 75390|
|Principal Investigator:||Brian Weiss||Children's Oncology Group|